Clinical Trial Search

Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients

Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519

Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants

Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability

Primary: Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration — 36.2; 32 percentage of change in maximum SUV

Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167

Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044

Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…

Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants

Primary: Event-free Survival After 12 Months — 78 percentage of participants

Primary: Progression-free Survival — 72 Percent

Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events

Primary: Toxicity as Assessed by NCI CTCAE v3.0 (Phase I) — 3; 3; 5; 2 Participants

Primary: 1-year Progression-free Survival — 31 Participants

Primary: Objective Tumor Response — 0 participants

Primary: Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) — 87 percentage of participants

Primary: Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses — 47; 8; 14 Participants

Primary: Progression-free Survival at 1 Year — 77 percentage of participants

Primary: Overall Response (OR) Rate — 36 Participants

Primary: Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL. — 3; 2 Participants

Primary: Complete Response Rate (CRR) — 73 Percentage of patients

Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants

Primary: Number of Patients Who Achieved Complete Response — 32 participants

Primary: Maximum Tolerated Dose (MTD) — 100 mg TAK-659

Primary: Overall Response (Complete Response + Partial Response) — 216; 94 Participants

Primary: Overall Survival — 56; 29 months

Primary: Complete Response (CR) Rate — 64.5; 63.5 percentage of participants — p=0.915

Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…

Primary: Overall Objective Response Rate During Treatment Cycle 1 — 57.1; 100.0; 30.8 percentage of participants